inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Items 101–200 of 1,000
Hoang, T. T., & Schweizer, H. P. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.17.5489-5497.1999 · Cited by 212
“terial isoniazid (2), and genetic evidence was obtained that M.”
BackgroundArmitige, L. Y., Jagannath, C., Wanger, A. R., & Norris, S. J. (2000) · Infection and Immunity · doi:10.1128/iai.68.2.767-778.2000 · Cited by 211
“These proteins have recently been found to possess mycolyl transferase activity (9), adding to the growing number of cell wall-synthetic enzymes identified in mycobacteria (3, 4, 6, 10).”
BackgroundFatty acid biosynthesis revisited: structure elucidation and metabolic engineering
Beld, J., Lee, D. J., & Burkart, M. D. (2014) · Molecular BioSystems · doi:10.1039/c4mb00443d · Cited by 212
Action Mechanism of Antitubercular Isoniazid
Lei, B., Wei, C.-J., & Tu, S.-C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2520 · Cited by 208
The genetics and biochemistry of isoniazid resistance in
Slayden, R. A., & Barry, C. E. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)00359-2 · Cited by 205
GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosismetabolism
Beste, D. J., Hooper, T., Stewart, G., Bonde, B., Avignone-Rossa, C., Bushell, M. E., Wheeler, P., Klamt, S., Kierzek, A. M., & McFadden, J. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r89 · Cited by 207
Larsen, M. H., Vilchèze, C., Kremer, L., Besra, G. S., Parsons, L., Salfinger, M., Heifets, L., Hazbon, M. H., Alland, D., Sacchettini, J. C., et al. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03162.x · Cited by 202
“Thus, these results clearly demonstrate that the M. tuberculosis inhA gene expressed from a heterologous promoter on a multicopy plasmid confers a >20-fold increased resistance to INH and a >10-fold increased © 2002 Blackwell Publishing Ltd, Molecular Microbiology, 46, 453–466 © 2002 Blackwell Publishing Ltd, Molecula…”
BackgroundResultSelf-citationMmpL3 is the flippase for mycolic acids in mycobacteria
Xu, Z., Meshcheryakov, V. A., Poce, G., & Chng, S.-S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700062114 · Cited by 201
“MAs are synthesized at the inner membrane (IM) as TMMs via a highly conserved and well-characterized pathway (2), which is the target of the first-line anti-TB drug isoniazid (3).”
BackgroundDiscovery of FabH/FabF Inhibitors from Natural Products
Young, K., Jayasuriya, H., Ondeyka, J. G., Herath, K., Zhang, C., Kodali, S., Galgoci, A., Painter, R., Brown-Driver, V., Yamamoto, R., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.519-526.2006 · Cited by 202
“(an anti-Mycobacterium tuberculosis agent) (2, 13).”
Reviving the antibiotic miracle?
Travis, J. (1994) · Science · doi:10.1126/science.8153615 · Cited by 202
Refined structures of β-ketoacyl-acyl carrier protein synthase III
Qiu, X., Janson, C. A., Smith, W. W., Head, M., Lonsdale, J., & Konstantinidis, A. K. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4457 · Cited by 197
Fatty acid biosynthesis in actinomycetes
Gago, G., Diacovich, L., Arabolaza, A., Tsai, S.-C., & Gramajo, H. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2010.00259.x · Cited by 191
“The inhA gene was identified as a putative target for INH (isoniazid) and ETH (ethionamide) in M. tuberculosis (Banerjee et al., 1994) and the InhA protein was demonstrated to catalyze the 2-trans-enoylACP reduction, with a preference for long-chain substrates (Quemard et al., 1995).”
BackgroundPortevin, D., de Sousa-D'Auria, C., Montrozier, H., Houssin, C., Stella, A., Lanéelle, M.-A., Bardou, F., Guilhot, C., & Daffé, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408578200 · Cited by 190
The mycobacterial cell wall: structure, biosynthesis and sites of drug action
Chatterjee, D. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80055-5 · Cited by 189
Towards a new tuberculosis drug: pyridomycin – nature's isoniazid
Hartkoorn, R. C., Sala, C., Neres, J., Pojer, F., Magnet, S., Mukherjee, R., Uplekar, S., Boy‐Röttger, S., Altmann, K., & Cole, S. T. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201689 · Cited by 188
Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13
Aggarwal, A., Parai, M. K., Shetty, N., Wallis, D., Woolhiser, L., Hastings, C., Dutta, N. K., Galaviz, S., Dhakal, R. C., Shrestha, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.025 · Cited by 183
“, the c-15t base change, further complicate the treatment of drug-resistant TB, conferring resistance not only to INH but also to the second-line TB drug ethionamide (ETH) (Banerjee et al., 1994), with reported frequencies of 35% and 55% in INHand ETH-resistant clinical isolates, respectively (Vilcheze and Jacobs, 201…”
BackgroundInfluentialChoi, K.-H., Kremer, L., Besra, G. S., & Rock, C. O. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003241200 · Cited by 188
Forty Years of Bacterial Fatty Acid Synthesis
Rock, C. O., & Jackowski, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.2022 · Cited by 187
New Targets and Screening Approaches in Antimicrobial Drug Discovery
Brown, E. D., & Wright, G. D. (2005) · Chemical Reviews · doi:10.1021/cr030116o · Cited by 186
Differential expression of mycobacterial proteins following phagocytosis by macrophages
Monahan, I. M., Betts, J., Banerjee, D. K., & Butcher, P. D. (2001) · Microbiology · doi:10.1099/00221287-147-2-459 · Cited by 187
“It is the primary target for the anti-tuberculous drug isoniazid (Banerjee et al., 1994).”
BackgroundThe Enoyl-[acyl-carrier-protein] Reductases FabI and FabL fromBacillus subtilis
Heath, R. J., Su, N., Murphy, C. K., & Rock, C. O. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005611200 · Cited by 184
Microevolution of extensively drug-resistant tuberculosis in Russia
Casali, N., Nikolayevskyy, V., Balabanova, Y., Ignatyeva, O., Kontsevaya, I., Harris, S. R., Bentley, S. D., Parkhill, J., Nejentsev, S., Hoffner, S. E., et al. (2012) · Genome Research · doi:10.1101/gr.128678.111 · Cited by 181
Luckner, S. R., Liu, N., am Ende, C. W., Tonge, P. J., & Kisker, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.090373 · Cited by 174
New Small-Molecule Synthetic Antimycobacterials
Ballell, L., Field, R. A., Duncan, K., & Young, R. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2153-2163.2005 · Cited by 177
Sacchettini, J. C., Ronning, D. R., Klabunde, T., Besra, G. S., Vissa, V., & Belisle, J. T. (2000) · Nature Structural Biology · doi:10.1038/72413 · Cited by 203
“, kills mycobacteria by inhibiting the biosynthesis of mycolic acid”
Suzuki, Y., Katsukawa, C., Tamaru, A., Abe, C., Makino, M., Mizuguchi, Y., & Taniguchi, H. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.5.1220-1225.1998 · Cited by 177
“tuberculosis (2, 4, 30, 32), and at least two genes are responsible for streptomycin resistance (12, 15, 21).”
BackgroundHameed, H. M. A., Islam, M. M., Chhotaray, C., Wang, C., Liu, Y., Tan, Y., Li, X., Tan, S., Delorme, V., Yew, W. W., et al. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00114 · Cited by 175
“The most frequently observed mutation in inhA regulatory region at position −15C/T is more generally associated with low level resistance to INH (MIC < 1µg/ml) (Banerjee et al., 1994; Fenner et al., 2012; Aye et al., 2016).”
BackgroundBabaoglu, K., Page, M. A., Jones, V. C., McNeil, M. R., Dong, C., Naismith, J. H., & Lee, R. E. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00673-5 · Cited by 175
Tuberculosis: The drug development pipeline at a glance
Villemagne, B., Crauste, C., Flipo, M., Baulard, A. R., Déprez, B., & Willand, N. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.033 · Cited by 172
The structural role of the carrier protein – active controller or passive carrier
Crosby, J., & Crump, M. P. (2012) · Natural Product Reports · doi:10.1039/c2np20062g · Cited by 173
Tuberculosis in Patients Infected with Human Immunodeficiency Virus: Perspective on the Past Decade
Shafer, R. W., & Edlin, B. R. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.4.683 · Cited by 174
“tuberculosis to drugs is caused by mutations in genes encoding the targets of anti-TB therapy [109-114].”
BackgroundTuberculosis drug discovery in the post‐post‐genomic era
Lechartier, B., Rybniker, J., Zumla, A., & Cole, S. T. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201201772 · Cited by 176
“Ethionamide (ETH) is an approved second-line drug but with considerable side effects (Weinstein et al , 1962) that inhibits the enoyl-ACP reductase, InhA, the target of isoniazid (INH), thus preventing mycolic acid synthesis (Banerjee et al , 1994).”
New tuberculosis drug targets, their inhibitors, and potential therapeutic impact
Shetye, G. S., Franzblau, S. G., & Cho, S. (2020) · Translational Research · doi:10.1016/j.trsl.2020.03.007 · Cited by 167
Engohang‐Ndong, J., Baillat, D., Aumercier, M., Bellefontaine, F., Besra, G. S., Locht, C., & Baulard, A. R. (2004) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03809.x · Cited by 169
Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis
Wilson, T. M., de Lisle, G. W., & Collins, D. M. (1995) · Molecular Microbiology · doi:10.1111/j.1365-2958.1995.tb02276.x · Cited by 166
“, 1991), and the use of extracts from both INH-sensitive and INH-resistant strains of Mycobacterium smegmatis confirmed that INH acted on this pathway (Banerjee et al., 1994)The development of INH resistance in MtbC strains is associated with a loss of catalase activjly (Middlebrook, 1954) and such strains have signif…”
BackgroundSelf-citationMycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis
Vilchèze, C., Av‐Gay, Y., Attarian, R., Liu, Z., Hazbón, M. H., Colangeli, R., Chen, B., Liu, W., Alland, D., Sacchettini, J. C., et al. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06365.x · Cited by 168
“Previous studies have shown four different mechanisms of ETH resistance in tubercle bacilli, including: (i) target modification (Banerjee et al., 1994; Vilcheze et al., 2006), (ii) target overexpression (Larsen et al., 2002), (iii) intracellular NADH/NAD+ ratio alteration (Miesel et al., 1998;…”
BackgroundSelf-citationEthA, a Common Activator of Thiocarbamide-Containing Drugs Acting on Different Mycobacterial Targets
Dover, L. G., Alahari, A., Gratraud, P., Gomes, J. M., Bhowruth, V., Reynolds, R. C., Besra, G. S., & Kremer, L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01063-06 · Cited by 168
“As activated ETH is known to inhibit mycolate synthesis by specifically targeting the enoyl-AcpM reductase InhA of FAS-II (1, 17), we tested whether TAC might alter FAS-II activity by determining the MICs of M.”
BackgroundInfluentialDiversity in enoyl-acyl carrier protein reductases
Massengo-Tiassé, R. P., & Cronan, J. E. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8704-7 · Cited by 164
The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis
Vilchèze, C., & Jacobs, W. R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.02.016 · Cited by 160
“Screening for hygromycin resistance allowed the selection of transductants that carried the mutated inhA, and these transductants were both INH and ETH resistant, demonstrating that the Ser94Ala mutation in inhA was sufficient to cause INH resistance inM. tuberculosis.”
BackgroundInfluentialSelf-citationAlland, D., Steyn, A. J., Weisbrod, T., Aldrich, K., & Jacobs, W. R. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.7.1802-1811.2000 · Cited by 165
“The enzymatic targets of many cell wall active antibiotics also have been discovered recently (7, 12, 25, 38).”
BackgroundSelf-citationGalactan Biosynthesis in Mycobacterium tuberculosis
Kremer, L., Dover, L. G., Morehouse, C., Hitchin, P., Everett, M., Morris, H. R., Dell, A., Brennan, P. J., McNeil, M. R., Flaherty, C., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102022200 · Cited by 162
Batt, S. M., Minnikin, D. E., & Besra, G. S. (2020) · Biochemical Journal · doi:10.1042/bcj20200194 · Cited by 183
Maccari, R., Ottanà, R., & Vigorita, M. G. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.065 · Cited by 158
Cohen, K. A., Manson, A. L., Desjardins, C. A., Abeel, T., & Earl, A. M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0660-8 · Cited by 163
“inhA Rv1484 NADH-dependent enoyl-acyl carrier protein Target amplification or modification [9, 10]”
BackgroundMarttila, H., Soini, H., Eerola, E., Vyshnevskaya, E. B., Vyshnevskiy, B. I., Otten, T. F., Vasilyef, A. V., & Viljanen, M. K. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2443 · Cited by 186
Sarkis, G. J., Jacobs, W. R., & Hatfull, G. F. (1995) · Molecular Microbiology · doi:10.1111/j.1365-2958.1995.tb02281.x · Cited by 172
Self-citationJohnsson, K., Froland, W. A., & Schultz, P. G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2834 · Cited by 160
Rouse, D. A., Li, Z., Bai, G. H., & Morris, S. L. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2472 · Cited by 160
“tuberculosis inhA gene sequence (1) and the M.”
BackgroundMethodInfluentialPrioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis
Hasan, S., Daugelat, S., Rao, P. S. S., & Schreiber, M. (2006) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0020061 · Cited by 159
Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis
Slayden, R. A., Lee, R. E., Armour, J. W., Cooper, A. M., Orme, I. M., Brennan, P. J., & Besra, G. S. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.12.2813 · Cited by 156
“The MICs of TLM against M. tuberculosis andM. smegmatis were 25 and 75 mg/ml, respectively, compared to the published value of 10 mg/ml for ethionamide against both species and 0.2 and 5 mg/ml for INH (1), respectively.”
BackgroundInfluentialMiesel, L., Weisbrod, T. R., Marcinkeviciene, J. A., Bittman, R., & Jacobs, W. R. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.9.2459-2467.1998 · Cited by 155
“Linkage analysis was performed to determine whether the newly acquired INH resistance was due to mutations in or near the inhA gene (3).”
BackgroundMethodInfluentialSelf-citationInhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides
He, X., Alian, A., & de Montellano, P. R. O. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.08.013 · Cited by 158
Fatty acid biosynthesis as a target for novel antibacterials.
Heath, R. J., & Rock, C. O. (2004) · PubMed · Cited by 156
Sreevatsan, S., Pan, X., Zhang, Y., Deretic, V. P., & Musser, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.600 · Cited by 152
Freundlich, J. S., Wang, F., Vilchèze, C., Gülten, G., Langley, R., Schiehser, G. A., Jacobus, D. P., Jacobs, W. R., & Sacchettini, J. C. (2009) · ChemMedChem · doi:10.1002/cmdc.200800261 · Cited by 151
Self-citationTaşdemir, D., Topaloğlu, B., Perozzo, R., Brun, R., O’Neill, R., Carballeira, N. M., Zhang, X., Tonge, P. J., Linden, A., & Rüedi, P. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.07.032 · Cited by 157
The Prodrug Activator EtaA from Mycobacterium tuberculosis Is a Baeyer-Villiger Monooxygenase
Fraaije, M. W., Kamerbeek, N. M., Heidekamp, A. J., Fortin, R., & Janssen, D. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307770200 · Cited by 152
Slayden, R. A., Lee, R. E., Jr., & Barry, C. E. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.02145.x · Cited by 172
“…have executed an elegant series of studies to identify the molecular target of INH, resulting in the identification of an enoyl acyl carrier protein (ACP) reductase called InhA that, when expressed on a multicopy plasmid, confers resistance to INH (Banerjee et al., 1994; Dessen et al., 1995).”
BackgroundVan Kessel, J. C., & Hatfull, G. F. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06109.x · Cited by 154
“…(STR), rifampicin (RIF) and ofloxacin (OFX); the gene targets tested are inhA, rpsL, rpoB and gyrA, in which the substitutions are inhA S94A (Banerjee et al., 1994), rpsL K43R (Karunakaran and Davies, 2000; Springer et al., 2001), rpoB H442R (Karunakaran and Davies, 2000) and gyrA A91V…”
BackgroundLarge-scale chemical–genetics yields new M. tuberculosis inhibitor classes
Johnson, E. O., LaVerriere, E., Office, E., Stanley, M., Meyer, E., Kawate, T., Gomez, J. E., Audette, R. E., Bandyopadhyay, N., Betancourt, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1315-z · Cited by 157
Allelic exchange in Mycobacterium tuberculosis with long linear recombination substrates
Balasubramanian, V, Pavelka, M. S., Bardarov, S. S., Martin, J., Weisbrod, T. R., McAdam, R. A., Bloom, B. R., & Jacobs, W. R. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.1.273-279.1996 · Cited by 150
“tuberculosis strains (13), and to determine the molecular genetic basis for resistance to isoniazid (3, 33).”
BackgroundSelf-citationMycobacterium smegmatis: The Vanguard of Mycobacterial Research
Sparks, I. L., Derbyshire, K. M., Jacobs, W. R., & Morita, Y. S. (2023) · Journal of Bacteriology · doi:10.1128/jb.00337-22 · Cited by 149
Self-citationMmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine
Su, C.-C., Klenotic, P. A., Bolla, J. R., Purdy, G. E., Robinson, C. V., & Yu, E. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901346116 · Cited by 148
“TMMs are synthesized in the cytoplasm via a highly conserved and well-characterized pathway (10), targeted by the first-line anti-TB drug isoniazid (11).”
BackgroundSchaeffer, M. L., Agnihotri, G., Volker, C., Kallender, H., Brennan, P. J., & Lonsdale, J. T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108903200 · Cited by 146
Mycobacterium tuberculosis Genes Induced during Infection of Human Macrophages
Dubnau, E., Fontán, P., Manganelli, R., Soares-Appel, S., & Smith, I. (2002) · Infection and Immunity · doi:10.1128/iai.70.6.2787-2795.2002 · Cited by 150
“smegmatis (1) without its promoter into the shuttle vector pYUB378 (9) to form the vector pJD32.”
BackgroundSelf-citationOhno, H., Koga, H., KOHNO, S., Tashiro, T., & Hara, K. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.1053 · Cited by 149
“512 2 2 Asp-526 (1), Trp-531 (1) 512 6 6 Leu-531 (3), Pro-526 (2), Arg-526 (1) 256 1 1 Tyr-516 and Asn-526 (1) 128 3 3 Leu-531 (2), Tyr-516 (1) 64 1 1 Leu-531 (1) 32 1 0 16 1 1 Leu-526 (1) 8 2 1 Gly-526 (1) 4 2 1 Val-516 (1) 2 0 0 1 2 1 Pro-533 (1) 0.”
Kremer, L., Nampoothiri, K. M., Lesjean, S., Dover, L. G., Graham, S., Betts, J., Brennan, P. J., Minnikin, D. E., Locht, C., & Besra, G. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103687200 · Cited by 147
Depletion of antibiotic targets has widely varying effects on growth
Wei, J.-R., Krishnamoorthy, V., Murphy, K., Kim, J.-H., Schnappinger, D., Alber, T., Sassetti, C. M., Rhee, K. Y., & Rubin, E. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018301108 · Cited by 149
“The cidal effects of reducing the level of InhA protein seen, albeit more slowly, with an inducible promoter substitution (17) suggest that, although isoniazid may target multiple enzymes (27–29), inhibition of InhA alone could account for antibiotic activity.”
BackgroundFlux Balance Analysis of Mycolic Acid Pathway: Targets for Anti-Tubercular Drugs
Raman, K., Rajagopalan, P., & Chandra, N. (2005) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0010046 · Cited by 145
“The topology of the curated reaction network clearly makes InhA an essential gene for the system, which is in agreement with its known role for mycobacterial survival [48].”
BackgroundInfluentialPasca, M. R., Guglierame, P., De Rossi, E., Zara, F., & Riccardi, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4775-4777.2005 · Cited by 145
“Partial DNA sequence analyses revealed that all the cosmids responsible for a high INH resistance contained the inhA gene (1) and were discarded.”
BackgroundNovel targets for tuberculosis drug discovery
Mdluli, K. E., & Spigelman, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.06.004 · Cited by 165
“Mycolic acid biosynthesis ENR (InhA) Not viable None Isoniazid [14,18,22] AcpM Not viable None [15] FabD Not viable None [15] FabH Not viable None Lauroyl-CoA [16,20] MabA Not viable None [17,21] KasA Not viable None Thiolactomycin [19] KasB Not viable None Thiolactomycin [19] MmaA4 None Attenuated [23] Pks13 Not viab…”
BackgroundBetts, J. C., McLaren, A., Lennon, M. G., Kelly, F. M., Lukey, P. T., Blakemore, S. J., & Duncan, K. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2903-2913.2003 · Cited by 144
“As thiolactomycin and triclosan both have well-defined targets, KasA/KasB and InhA, respectively, they have previously been used as tools to study the molecular mechanism of isoniazid and the relative contributions of InhA and KasA in an effort to address the controversy surrounding the primary target of isoniazid (29…”
BackgroundInfluentialHeifets, L. B., & Cangelosi, G. A. (1999) · PubMed · Cited by 177
Hirano, K., Abe, C., & Takahashi, M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.8.2663-2666.1999 · Cited by 149
“4) Ind (1), Mya (1), Thai (2) His 526 Tyr 8 (8.”
BackgroundInfluentialReversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
Blondiaux, N., Moune, M., Desroses, M., Frita, R., Flipo, M., Mathys, V., Soetaert, K., Kiass, M., Delorme, V., Djaout, K., et al. (2017) · Science · doi:10.1126/science.aag1006 · Cited by 148
Genetic strategies for antibacterial drug discovery
Miesel, L., Greene, J. R., & Black, T. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1086 · Cited by 152
The AhpC and AhpD Antioxidant Defense System of Mycobacterium tuberculosis
Hillas, P. J., del Alba, F. S., Oyarzábal, J., Wilks, A., & de Montellano, P. R. O. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001001200 · Cited by 140
Alahari, A., Trivelli, X., Guérardel, Y., Dover, L. G., Besra, G. S., Sacchettini, J. C., Reynolds, R. C., Coxon, G. D., & Kremer, L. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001343 · Cited by 157
“Mycolic acids are also the targets of front-line antitubercular drugs, such as isoniazid (INH) and ETH [18,19,20].”
BackgroundInfluentialBacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery
Payne, D. J., Warren, P. V., Holmes, D. J., Ji, Y., & Lonsdale, J. T. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01774-3 · Cited by 140
Opposing effects of target overexpression reveal drug mechanisms
Palmer, A. C., & Kishony, R. (2014) · Nature Communications · doi:10.1038/ncomms5296 · Cited by 162
Mechanisms of Drug Resistance in Mycobacterium tuberculosis
Cole, S. T. (1994) · Immunobiology · doi:10.1016/s0171-2985(11)80466-3 · Cited by 140
Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen
Favrot, L., Grzegorzewicz, A. E., Lajiness, D. H., Marvin, R. K., Boucau, J., Isailović, D., Jackson, M., & Ronning, D. R. (2013) · Nature Communications · doi:10.1038/ncomms3748 · Cited by 143
Mycobacterial FurA is a negative regulator of catalase-peroxidase gene katG
Zahrt, T. C., Song, J., Siple, J., & Deretic, V. (2001) · Molecular Microbiology · doi:10.1046/j.1365-2958.2001.02321.x · Cited by 138
“In parallel to the potential role in pathogenicity, these and additional determinants have been shown to participate in acquired resistance (Zhang et al., 1992; Banerjee et al., 1994; Heym et al., 1995; Musser, 1995; Rouse and Morris, 1995; Mdluli et al., 1998) and innate susceptibility to isonicotinic acid hydrazide…”
BackgroundUse of genomics and combinatorial chemistry in the development of new antimycobacterial drugs
Barry, C. E., Slayden, R. A., Sampson, A. E., & Lee, R. E., Jr. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00253-1 · Cited by 136
Kiepiela, P., Bishop, K. S., Smith, A. N., Roux, L., & York, D. F. (2000) · Tubercle and Lung Disease · doi:10.1054/tuld.1999.0231 · Cited by 153
Biocides – resistance, cross-resistance mechanisms and assessment
Gnanadhas, D. P., Marathe, S. A., & Chakravortty, D. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.748035 · Cited by 141
“Similarly in Mycobacterium tuberculosis the analog of fabI (inhA) is the target for isoniazid and ethionamide where a point mutation in inhA gene confers resistance to drugs [48].”
BackgroundMutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis
Hirano, K., Takahashi, M., Kazumi, Y., Fukasawa, Y., & Abe, C. (1998) · Tubercle and Lung Disease · doi:10.1016/s0962-8479(98)80004-x · Cited by 163
Basso, L. A., Zheng, R., Musser, J. M., Jacobs, W. R., & Blanchard, J. S. (1998) · The Journal of Infectious Diseases · doi:10.1086/515362 · Cited by 163
“phenotype were shown to be resistant to inhibition of mycolic acid biosynthesis by INH [11].”
BackgroundResultInfluentialSelf-citationBrossier, F., Véziris, N., Truffot-Pernot, C., Jarlier, V., & Sougakoff, W. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01054-06 · Cited by 131
“INH inhibits InhA, the enoyl-ACPreductase, which is a key enzyme for the biosynthesis of mycolic acids found in the cell wall (2).”
BackgroundSeidel, M., Alderwick, L. J., Birch, H. L., Sahm, H., Eggeling, L., & Besra, G. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700271200 · Cited by 133
Heym, B., Stavropoulos, E., Honoré, N., Domenech, P., Saint-Joanis, B., Wilson, T. M., Collins, D. M., Colston, M. J., & Cole, S. T. (1997) · Infection and Immunity · doi:10.1128/iai.65.4.1395-1401.1997 · Cited by 131
“One of the reaction intermediates (14) affects a second mycobacterial protein, InhA, which is an acyl carrier protein-enoyl reductase involved in mycolic acid synthesis (1, 6); the modified InhA is no longer active, and fatty acid synthesis is affected.”
BackgroundSelf-citationThe DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
Riccardi, G., Pasca, M. R., Chiarelli, L. R., Manina, G., Mattevi, A., & Binda, C. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5218-x · Cited by 135
Torres, M. J., Criado, A., Palomares, J. C., & Aznar, J. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.9.3194-3199.2000 · Cited by 144
“Several studies have reported alterations in at least four genes, katG, inhA, ahpC, and kasA (1, 10, 12, 21, 24).”
BackgroundChigutsa, E., Pasipanodya, J. G., Visser, M. E., van Helden, P. D., Smith, P. J., Sirgel, F. A., Gumbo, T., & McIlleron, H. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03931-14 · Cited by 133
“Isoniazid is a prodrug whose active moiety primarily targets the enoyl-acyl carrier protein reductase of the fatty acid synthase II (FASII) (40), and this might antagonize the effect of pyrazinamide on the pathway (41).”
BackgroundInterventions for tuberculosis control and elimination.
Rieder, H. L., & Disease, L. (2002) · Cited by 162
Marrakchi, H., Ducasse-Cabanot, S., Labesse, G., Montrozier, H. L., Margeat, E., Emorine, L. J., Charpentier, X., Daffé, M., & Quémard, A. (2002) · Microbiology · doi:10.1099/00221287-148-4-951 · Cited by 158
“Likewise, local rearrangements of the substrate-binding pocket of InhA and ThnR were observed upon binding of the substrate or an inhibitor (Rozwarski et al., 1999; Andersson et al., 1996 ).”
BackgroundA fatty-acid synthesis mechanism specialized for parasitism
Lee, S. H., Stephens, J. L., & Englund, P. T. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1617 · Cited by 155
Design, Synthesis, and Biological Evaluation of New Cinnamic Derivatives as Antituberculosis Agents
De, P., Yoya, G. K., Constant, P., Bedos‐Belval, F., Duran, H., Saffon‐Merceron, N., Daffé, M., & Baltas, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101510d · Cited by 128
Organization of the mycobacterial cell wall: a nanoscale view
Alsteens, D., Verbelen, C., Dague, É., Raze, D., Baulard, A. R., & Dufrêne, Y. F. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-007-0386-0 · Cited by 139
“Ethionamide (ETH) and isoniazid (INH) inhibit the enoyl ACP reductase InhA involved in the biosynthesis of mycolic acids [2], while the synthesis of the glycosylated portion of the wall is efficiently inhibited by ethambutol (EMB), which targets arabinosyltransferases [4].”
BackgroundResultInhibition of the fungal fatty acid synthase type I multienzyme complex
Johansson, P., Wiltschi, B., Kumari, P., Kessler, B., Vonrhein, C., Vonck, J., Oesterhelt, D., & Grininger, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805827105 · Cited by 127
“This potential is further underlined by the potency of the classic drugs isoniazid and triclosan, both inhibiting the ER step of bacterial fatty acid biosynthesis (6, 7).”
Background
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.